Identification of aspirin analogues that repress NF-κB signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo

Claudius,Ann-Katrin; Kankipati,Chandra   S.; Kilari,Rajagopal  S.; Hassan,Sadiya; Guest,Kerry; Russell,Steven  T.; Perry,Chris  J.; Stark,Lesley  A.; Nicholl,Iain  D.

doi:10.3892/or.2014.3373

Identification of aspirin analogues that repress NF-κB signalling and demonstrate anti-proliferative activity towards colorectal cancer in vitro and in vivo

Authors:
- Ann-Katrin Claudius
- Chandra S. Kankipati
- Rajagopal S. Kilari
- Sadiya Hassan
- Kerry Guest
- Steven T. Russell
- Chris J. Perry
- Lesley A. Stark
- Iain D. Nicholl
View Affiliations

Affiliations: Edinburgh Cancer Research Centre and MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK, The Research Institute in Healthcare Science, Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton WV1 1LY, UK, Life and Health Sciences, Aston Triangle, Aston University, Birmingham B4 7ET, UK
Published online on: July 31, 2014 https://doi.org/10.3892/or.2014.3373
Pages: 1670-1680

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Substantial evidence indicates that aspirin and related non-steroidal anti-inflammatory drugs (NSAIDs) have potential as chemopreventative/therapeutic agents. However, these agents cannot be universally recommended for prevention purposes due to their potential side-effect profiles. Here, we compared the growth inhibitory and mechanistic activity of aspirin to two novel analogues, diaspirin (DiA) and fumaryl diaspirin (F-DiA). We found that the aspirin analogues inhibited cell proliferation and induced apoptosis of colorectal cancer cells at significantly lower doses than aspirin. Similar to aspirin, we found that an early response to the analogues was a reduction in levels of cyclin D1 and stimulation of the NF-κB pathway. This stimulation was associated with a significant reduction in basal levels of NF-κB transcriptional activity, in keeping with previous data for aspirin. However, in contrast to aspirin, DiA and F-DiA activity was not associated with nucleolar accumulation of RelA. For all assays, F-DiA had a more rapid and significant effect than DiA, identifying this agent as particularly active against colorectal cancer. Using a syngeneic colorectal tumour model in mice, we found that, while both agents significantly inhibited tumour growth in vivo, this effect was particularly pronounced for F-DiA. These data identify two compounds that are active against colorectal cancer in vitro and in vivo. They also identify a potential mechanism of action of these agents and shed light on the chemical structures that may be important for the antitumour effects of aspirin.

View Figures

View References

1	Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
2	Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 325:1593–1596. 1991. View Article : Google Scholar : PubMed/NCBI
3	Logan RF, Little J, Hawtin PG and Hardcastle JD: Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ. 307:285–289. 1993. View Article : Google Scholar
4	Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 348:891–899. 2003. View Article : Google Scholar : PubMed/NCBI
5	Din FV, Theodoratou E, Farrington SM, et al: Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 59:1670–1679. 2010. View Article : Google Scholar : PubMed/NCBI
6	La Vecchia C, Negri E, Franceschi S, et al: Aspirin and colorectal cancer. Br J Cancer. 76:675–677. 1997.
7	Corpet DE and Pierre F: Point: from animal models to prevention of colon cancer. Systematic review of chemoprevention in min mice and choice of the model system. Cancer Epidemiol Biomarkers Prev. 12:391–400. 2003.PubMed/NCBI
8	Liu Y, Ju J, Xiao H, et al: Effects of combination of calcium and aspirin on azoxymethane-induced aberrant crypt foci formation in the colons of mice and rats. Nutr Cancer. 60:660–665. 2008. View Article : Google Scholar : PubMed/NCBI
9	Bousserouel S, Gosse F, Bouhadjar M, Soler L, Marescaux J and Raul F: Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a pre-clinical model of colon carcinogenesis. Oncol Rep. 23:511–517. 2010.
10	Sansom OJ, Stark LA, Dunlop MG and Clarke AR: Suppression of intestinal and mammary neoplasia by lifetime administration of aspirin in Apc(Min/+) and Apc(Min/+), Msh2(−/−) mice. Cancer Res. 61:7060–7064. 2001.PubMed/NCBI
11	Lal G, Ash C, Hay K, et al: Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res. 61:6131–6136. 2001.PubMed/NCBI
12	Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP and Meade TW: Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 377:31–41. 2011. View Article : Google Scholar : PubMed/NCBI
13	Burn J, Gerdes AM, Macrae F, et al: Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 378:2081–2087. 2011. View Article : Google Scholar
14	Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW and Mehta Z: Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 379:1591–1601. 2012. View Article : Google Scholar : PubMed/NCBI
15	Chan AT, Ogino S and Fuchs CS: Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 302:649–658. 2009. View Article : Google Scholar : PubMed/NCBI
16	Laine L: The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum. 32:25–32. 2002. View Article : Google Scholar : PubMed/NCBI
17	Gasche C, Goel A, Natarajan L and Boland CR: Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res. 65:3993–3997. 2005. View Article : Google Scholar : PubMed/NCBI
18	Campregher C, Honeder C, Chung H, Carethers JM and Gasche C: Mesalazine reduces mutations in transforming growth factor β receptor II and activin type II receptor by improvement of replication fidelity in mononucleotide repeats. Clin Cancer Res. 16:1950–1956. 2010.PubMed/NCBI
19	McIlhatton MA, Tyler J, Burkholder S, et al: Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res. 67:10966–10975. 2007. View Article : Google Scholar
20	Tesei A, Zoli W, Fabbri F, et al: NCX 4040, an NO-donating acetylsalicylic acid derivative: efficacy and mechanisms of action in cancer cells. Nitric Oxide. 19:225–236. 2008. View Article : Google Scholar : PubMed/NCBI
21	Selvendiran K, Bratasz A, Tong L, Ignarro LJ and Kuppusamy P: NCX-4016, a nitro-derivative of aspirin, inhibits EGFR and STAT3 signaling and modulates Bcl-2 proteins in cisplatin-resistant human ovarian cancer cells and xenografts. Cell Cycle. 7:81–88. 2008. View Article : Google Scholar : PubMed/NCBI
22	Zhao W, Mackenzie GG, Murray OT, Zhang Z and Rigas B: Phosphoaspirin (MDC-43), a novel benzyl ester of aspirin, inhibits the growth of human cancer cell lines more potently than aspirin: a redox-dependent effect. Carcinogenesis. 30:512–519. 2009. View Article : Google Scholar : PubMed/NCBI
23	Wang D and DuBois RN: Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett. 267:197–203. 2008. View Article : Google Scholar : PubMed/NCBI
24	Sheng H, Shao J, Morrow JD, Beauchamp RD and DuBois RN: Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58:362–366. 1998.PubMed/NCBI
25	Harris RE, Beebe-Donk J and Alshafie GA: Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer. 8:2372008. View Article : Google Scholar : PubMed/NCBI
26	Elwood PC, Gallagher AM, Duthie GG, Mur LA and Morgan G: Aspirin, salicylates, and cancer. Lancet. 373:1301–1309. 2009. View Article : Google Scholar : PubMed/NCBI
27	Dibra HK, Perry CJ and Nicholl ID: Non-steroidal anti-inflammatory drugs, DNA repair and cancer. DNA Repair and Human Health. Vengrova S: InTech; pp. 743–776. 2011, http://cdn.intechopen.com/pdfs-wm/22182.pdf.
28	Kopp E and Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 265:956–959. 1994. View Article : Google Scholar : PubMed/NCBI
29	Thoms HC, Dunlop MG and Stark LA: p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res. 67:1660–1669. 2007. View Article : Google Scholar : PubMed/NCBI
30	Yu HG, Huang JA, Yang YN, et al: The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest. 32:838–846. 2002. View Article : Google Scholar : PubMed/NCBI
31	Luciani MG, Campregher C and Gasche C: Aspirin blocks proliferation in colon cells by inducing a G1 arrest and apoptosis through activation of the checkpoint kinase ATM. Carcinogenesis. 28:2207–2217. 2007. View Article : Google Scholar : PubMed/NCBI
32	Shureiqi I, Chen D, Lotan R, et al: 15-Lipoxygenase-1 mediates nonsteroidal anti-inflammatory drug-induced apoptosis independently of cyclooxygenase-2 in colon cancer cells. Cancer Res. 60:6846–6850. 2000.PubMed/NCBI
33	Goel A, Chang DK, Ricciardiello L, Gasche C and Boland CR: A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res. 9:383–390. 2003.PubMed/NCBI
34	Pangburn HA, Kraus H, Ahnen DJ and Rice PL: Sulindac metabolites inhibit epidermal growth factor receptor activation and expression. J Carcinog. 4:162005. View Article : Google Scholar : PubMed/NCBI
35	Pangburn HA, Ahnen DJ and Rice PL: Sulindac metabolites induce proteosomal and lysosomal degradation of the epidermal growth factor receptor. Cancer Prev Res. 3:560–572. 2010. View Article : Google Scholar : PubMed/NCBI
36	Ruschoff J, Wallinger S, Dietmaier W, et al: Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci USA. 95:11301–11306. 1998. View Article : Google Scholar
37	Deb J, Dibra H, Shan S, et al: Activity of aspirin analogues and vanillin in a human colorectal cancer cell line. Oncol Rep. 26:557–565. 2011.PubMed/NCBI
38	Hussey HJ and Tisdale MJ: Effect of polyunsaturated fatty acids on the growth of murine colon adenocarcinomas in vitro and in vivo. Br J Cancer. 70:6–10. 1994. View Article : Google Scholar : PubMed/NCBI
39	Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
40	Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 47:936–942. 1987.PubMed/NCBI
41	Stark LA and Dunlop MG: Nucleolar sequestration of RelA (p65) regulates NF-κB-driven transcription and apoptosis. Mol Cell Biol. 25:5985–6004. 2005.PubMed/NCBI
42	Stark LA, Din FV, Zwacka RM and Dunlop MG: Aspirin-induced activation of the NF-κB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J. 15:1273–1275. 2001.
43	Loveridge CJ, MacDonald AD, Thoms HC, Dunlop MG and Stark LA: The proapoptotic effects of sulindac, sulindac sulfone and indomethacin are mediated by nucleolar translocation of the RelA(p65) subunit of NF-κB. Oncogene. 27:2648–2655. 2008.PubMed/NCBI
44	Campbell KJ, Rocha S and Perkins ND: Active repression of antiapoptotic gene expression by RelA(p65) NF-κB. Mol Cell. 13:853–865. 2004.PubMed/NCBI
45	Walder JA, Zaugg RH, Walder RY, Steele JM and Klotz IM: Diaspirins that cross-link beta chains of hemoglobin: bis(3,5-dibromosalicyl) succinate and bis(3,5-dibromosalicyl) fumarate. Biochemistry. 18:4265–4270. 1979. View Article : Google Scholar : PubMed/NCBI
46	Alfonso LF, Srivenugopal KS and Bhat GJ: Does aspirin acetylate multiple cellular proteins? (Review). Mol Med Rep. 2:533–537. 2009.PubMed/NCBI
47	Schwenger P, Alpert D, Skolnik EY and Vilcek J: Cell typespecific activation of c-Jun N-terminal kinase by salicylates. J Cell Physiol. 179:109–114. 1999. View Article : Google Scholar : PubMed/NCBI
48	Kojima M, Morisaki T, Sasaki N, et al: Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res. 24:675–681. 2004.PubMed/NCBI
49	Greenspan EJ, Madigan JP, Boardman LA and Rosenberg DW: Ibuprofen inhibits activation of nuclear β-catenin in human colon adenomas and induces the phosphorylation of GSK-3β. Cancer Prev Res. 4:161–171. 2011.
50	Thoms HC, Loveridge CJ, Simpson J, et al: Nucleolar targeting of RelA(p65) is regulated by COMMD1-dependent ubiquitination. Cancer Res. 70:139–149. 2010. View Article : Google Scholar : PubMed/NCBI
51	Meltzer PC, Blundell P, Yong YF, et al: 2-Carbomethoxy-3-aryl-8-bicyclo[3.2.1]octanes: potent non-nitrogen inhibitors of monoamine transporters. J Med Chem. 43:2982–2991. 2000.PubMed/NCBI